Humalog (insulin lispro) is a rapid-acting insulin analog used to control blood sugar spikes at mealtimes in adults and children with type 1 or type 2 diabetes. It begins working within 15 minutes of injection, peaks in about 1 hour, and lasts 2 to 4 hours. Three products carry the insulin lispro molecule: brand-name Humalog (Eli Lilly), Admelog (Sanofi, a follow-on biologic approved in 2017), and Lyumjev (Eli Lilly, an ultra-rapid formulation with citrate and treprostinil added to speed absorption).
Eli Lilly cut the list price of Humalog by 70% in May 2023, bringing the brand 10 mL vial from as high as $274 down to $72 to $86. The company simultaneously launched an authorized generic insulin lispro at $25 per vial. Despite these cuts, patients without assistance programs have historically faced substantial out-of-pocket costs. The $35 per month cap under Medicare Part D from the Inflation Reduction Act has provided the most consistent relief for Medicare enrollees since January 2023. For a broader look at insulin pricing across formulations, see the insulin cost guide.
For inpatient hospital stays, insulin lispro is typically bundled into the DRG (Diagnosis Related Group) payment and does not appear as a separate line item on the bill. This differs from some biologics and chemotherapy agents billed as separate Part B drug charges. When insulin does appear on a hospital itemized bill (mainly in outpatient or emergency department settings), it may carry a facility markup of 5x to 20x the acquisition cost. Knowing the relevant J-codes (J1815 for injectable insulin per 5 units, J1817 for insulin pump supply) helps patients spot billing errors. Patients who need help covering cost-sharing should check whether they qualify for the Lilly Cares Foundation PAP or Medicaid.
What Humalog Costs by Point of Pay (2026)
The price you pay depends almost entirely on WHERE you pay. The same humalog can cost many times more at a hospital than at your local pharmacy:
2026 Humalog Price by Point of Pay| Where you pay | Typical cost | Notes |
|---|
| Medicare ASP rate (Part B, J1815) | ~$1.75 per 5-unit billing unit | CMS quarterly Part B ASP rate. Used when insulin is billed in clinical settings, not covered under Part D. |
| Pharmacy counter (retail, no insurance) | $25 - $160/vial or pen | Generic lispro $25/vial; brand Humalog $72-$86/vial; KwikPen 5-pack up to $160 |
| Medicare Part D (monthly cap) | $35/month | Inflation Reduction Act 2022, effective January 2023. No deductible applies to insulin. |
| Lilly Insulin Value Program (commercial or uninsured) | $35/month | Any Lilly insulin (Humalog, Lyumjev, generic lispro). Not available to Medicare or Medicaid enrollees. |
| Inpatient hospital stay | Bundled in DRG, not separately billed | Insulin is bundled into the hospital DRG payment for most inpatient admissions. Itemized charges may appear in outpatient or ED settings. |
| Medicaid | $1 - $4/prescription | Nominal copay in all 50 states |
Retail prices reflect post-2023 list prices after Lilly's 70% price reduction. Medicare Part D $35 cap is statutory under the IRA effective January 2023. ASP rates are CMS quarterly published figures.
Source: CMS Medicare Part B ASP 2026, Eli Lilly price announcements, CMS Inflation Reduction Act insulin cap, GoodRx 2026
Why Hospitals Charge So Much
For most inpatient hospital stays, insulin is bundled into the DRG (Diagnosis Related Group) payment. This means the hospital receives a fixed lump sum for a diabetes-related admission, and insulin is considered part of that bundle rather than billed as a separate drug charge. Patients generally will not see insulin as a distinct line item on an inpatient bill under DRG-based reimbursement. This is an important difference from branded biologics, where hospitals may bill the drug as a separate Part B charge.
The exception is outpatient hospital visits and emergency department encounters, where drugs can appear as separate line items. In those settings, hospitals apply a facility rate that includes drug acquisition cost plus overhead, supply, and administration markups. Insulin that costs $25 to $86 per vial at retail may appear as $150 to $400 or more on an outpatient facility bill. The HCPCS J1815 code (injection, insulin, per 5 units) is used to itemize those charges, and reviewing the unit count billed against actual doses received is the primary way to catch overcharges.
Lilly's 2023 price cut and the IRA's $35 monthly Part D cap have together reduced the financial burden for the most vulnerable patients, but chargemasters at hospitals and outpatient infusion centers are updated slowly and may still reflect older acquisition prices. Asking for an itemized bill and cross-referencing the J1815 unit count is the most actionable step when a charge looks wrong. For Part B billed insulin, the 2026 Medicare coinsurance is 20% after the $283 Part B deductible.
HCPCS J-Codes: What Appears on Your Bill
Insulin lispro can appear on hospital and outpatient bills with two HCPCS Level II J-codes. These codes are public domain and you can use them to verify what you were billed:
HCPCS J-codes for Humalog| Code | Description | What to look for |
|---|
| J1815 | Injection, insulin, per 5 units | Standard hospital insulin billing. A 20-unit dose = 4 billing units of J1815. Check the unit count against your actual dose. Applies to all insulin types including rapid-acting lispro. |
| J1817 | Insulin for use with insulin pump (per 50 units) | Only for patients using an insulin pump covered under Medicare Part B DME benefit. Should NOT appear on a bill if you do not use a pump. J1817 covers 50 units per billing unit. Being billed J1817 instead of J1815 would greatly inflate costs for non-pump patients. |
HCPCS Level II codes are public domain. J1815 covers all rapid-acting insulins, not just lispro. Verify the brand billed matches what you actually received. Humalog, Admelog, and generic lispro all use J1815.
Source: CMS HCPCS Level II Coding, CMS Medicare Part B Drug Coverage
Patient Assistance Programs
Eli Lilly runs two separate programs for Humalog. The Lilly Insulin Value Program is a pharmacy savings program available to anyone with commercial insurance or no insurance, capping cost at $35 per month. The Lilly Cares Foundation is a separate patient assistance program that provides free insulin to income-qualifying patients. Sanofi runs a parallel program for Admelog (the insulin lispro follow-on product). Medicare Part D patients already have a $35/month statutory cap and typically do not need manufacturer programs.
Patient assistance programs for Humalog| Manufacturer program | Cost / Benefit | How to apply |
|---|
| Lilly Insulin Value Program | $35/month for Humalog, Lyumjev, or Eli Lilly generic insulin lispro. Any commercially insured or uninsured patient. Not available to Medicare or Medicaid enrollees. | insulinaffordability.com |
| Lilly Cares Foundation (PAP) | Free Humalog for uninsured or Medicare Part D patients with household income up to 400% Federal Poverty Level ($62,400 for a single person, $127,500 for a family of four in 2026) | lillycares.com |
| Sanofi Insulins VALyou Savings (Admelog) | $35/month for Admelog (insulin lispro) for commercially insured or uninsured patients. Not available to Medicare or Medicaid enrollees. | sanofipatientconnection.com |
Medicare Part D patients do not need manufacturer programs. The IRA $35/month insulin cap applies automatically through your Part D plan. Eligibility varies by program. Income thresholds use federal poverty guidelines updated annually.
Source: insulinaffordability.com, lillycares.com, sanofipatientconnection.com, NeedyMeds.org
Medicare Part D Coverage for Humalog
If you are enrolled in Medicare Part D, your out-of-pocket cost for insulin lispro (Humalog, Admelog, Lyumjev, or the generic) is capped at $35 per month. This cap comes from the Inflation Reduction Act, signed August 16, 2022, and effective January 1, 2023. It is statutory law, not a plan option. The cap applies regardless of which Part D plan you have, which insulin brand you use, and whether you have met your deductible. If your pharmacy charges more than $35 per month for insulin and you have Part D, call your plan's member services. This is a billing error.
The $35 cap could be lower than $35 if 25% of the plan's negotiated price for that insulin falls below $35. The 2026 annual Part D out-of-pocket maximum is $2,100 for all covered drugs combined, but the $35 monthly insulin cap provides an earlier, product-specific floor. Medicare Part B covers insulin only when used with a covered insulin pump (DME benefit). The same $35/month IRA cap applies in that context too. Humalog (insulin lispro) is NOT one of the IRA's first 10 Medicare-negotiated drugs; insulin aspart (Fiasp/NovoLog) is. Humalog receives the flat $35 statutory cap, which applies to all insulins regardless of negotiation status.
Common Humalog Billing Errors
Billing errors involving insulin lispro fall into two categories: outpatient and hospital facility errors, and pharmacy coverage errors. Check for these before paying any insulin bill:
- J1817 billed instead of J1815 for patients who do not use an insulin pump. J1817 covers 50 units per billing unit, inflating the charge substantially. Confirm you use a pump before accepting this code.
- Unit count inflated: J1815 covers 5 administered units per billing unit. A 10-unit dose = 2 billing units; a 20-unit dose = 4 billing units. Verify the billed unit count matches actual units administered per your medication administration record.
- Brand substitution billing error: Humalog billed when Admelog or generic lispro was actually administered, or vice versa. The active molecule is identical but list prices differ. Confirm the brand billed matches administration records.
- Rapid-acting vs long-acting confusion: Humalog (lispro) and NovoLog (aspart) are rapid-acting prandial insulins. Lantus (glargine), Basaglar, Semglee, and Rezvoglar are long-acting basal insulins, a completely different drug class. These use different J-codes and different price tiers. Being billed for the wrong insulin type is a known error after hospital pharmacy substitutions.
- Part D overcharge: Medicare Part D patient charged more than $35 per month for insulin at the pharmacy. This is a plan billing error. The IRA $35 cap is statutory and applies regardless of plan or deductible status. Contact plan member services immediately.
- Insulin billed as a separate outpatient charge when it was administered during an inpatient DRG admission. For DRG-covered admissions, insulin should be bundled into the DRG payment, not billed separately.
Frequently Asked Questions
How much does Humalog cost in 2026 without insurance?
Brand Humalog 10 mL vials list at $72 to $86 after Lilly's 2023 price cut. Eli Lilly's authorized generic insulin lispro is available at $25 per vial. KwikPens (5-pack) run $90 to $160. However, the Lilly Insulin Value Program caps cost at $35 per month for any uninsured patient, so most uninsured patients should pay no more than $35/month total.
Does Medicare cover Humalog insulin in 2026?
Yes. Medicare Part D covers Humalog and its equivalents, with patient cost capped at $35 per month under the Inflation Reduction Act of 2022 (effective January 2023). This cap is statutory and applies to all Part D plans and all insulin brands. Medicare Part B covers insulin only when used with a covered insulin pump (DME benefit), capped at $35 per month under the same law. The 2026 Part D annual out-of-pocket maximum is $2,100, but the $35 insulin cap applies before that threshold.
What is Admelog and is it a biosimilar of Humalog?
Admelog (Sanofi) is an FDA-approved follow-on insulin lispro product, approved in 2017. It contains the same active molecule as Humalog (insulin lispro 100 units/mL) and has equivalent clinical efficacy for mealtime dosing. Admelog is sometimes called a biosimilar in common usage, but it is NOT FDA-designated interchangeable with Humalog, so a pharmacist cannot automatically substitute it without a new prescription in most states. Sanofi caps Admelog at $35/month through its VALyou program.
What is the difference between Humalog (rapid-acting) and Lantus or Basaglar (long-acting)?
Humalog (insulin lispro) is a rapid-acting prandial insulin injected at mealtimes to control blood sugar from food. It works within 15 minutes and lasts 2 to 4 hours. Lantus (insulin glargine), Basaglar, Semglee, and Rezvoglar are long-acting basal insulins injected once daily for 18 to 24 hours of steady background coverage. They serve different physiological roles, use different J-codes, and have different pricing tiers. Basaglar, Semglee, and Rezvoglar are biosimilars of Lantus, not of Humalog.
What is HCPCS J1815 and what does it mean on my hospital bill?
HCPCS J1815 is the billing code for Injection, insulin, per 5 units, the code used for insulin administered in a clinical setting on hospital and outpatient claims. It covers all rapid-acting insulins including lispro. One billing unit equals 5 administered units, so a 20-unit dose = 4 J1815 units. If your bill shows a high unit count multiplied by a per-unit charge well above retail value, investigate. For most inpatient DRG admissions, insulin is bundled and will not appear as a J1815 line item.
Is Lyumjev the same as Humalog?
Lyumjev (insulin lispro-aabc) is a Lilly product containing the same insulin lispro molecule as Humalog, plus citrate and treprostinil to accelerate absorption. It is classified as ultra-rapid-acting, with onset faster than standard Humalog. It is approved for adults with type 1 or type 2 diabetes. Lyumjev is covered by the Lilly Insulin Value Program at $35/month. It is not FDA-interchangeable with Humalog and is not a biosimilar of any long-acting insulin.
What patient assistance programs are available for Humalog?
Two Lilly programs cover Humalog. The Lilly Insulin Value Program (insulinaffordability.com) caps cost at $35/month for commercially insured or uninsured patients. No income verification required. The Lilly Cares Foundation (lillycares.com) provides free insulin to uninsured patients and Medicare Part D patients with income up to 400% of the Federal Poverty Level (roughly $62,400 for a single person in 2026). Medicare Part D patients already have a $35/month statutory cap and generally do not need the manufacturer program.
Why does insulin sometimes appear on a hospital bill at very high prices?
When insulin does appear as a separate line item on a hospital bill, mainly in outpatient or emergency department settings, it reflects a facility charge that includes the drug acquisition cost plus overhead, nursing administration, and supply fees. Hospitals apply a facility markup, sometimes 5x to 20x the acquisition cost. For inpatient DRG admissions, insulin is bundled into the overall payment and should not appear as a separate drug charge. If you see insulin listed separately on an inpatient bill, that is worth disputing.
